Table 1 Efficacy, tolerability and patient satisfaction of co-enzyme Q10 and amitriptyline in the treatment of cyclic vomiting syndrome
From: Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study
Amitriptyline | Co-enzyme Q10 | |||||
|---|---|---|---|---|---|---|
Pediatric Onset1<18 y | Adult Onset ≥18 y | All Subjects | Pediatric Onset1<18 y | Adult Onset ≥18 y | All Subjects | |
Episode Frequency 2 | 62/113 | 26/49 | 88/162 | 10/17 | 1/5 | 11/22 |
55% | 53% | 54% | 59% | 20% | 50% | |
Episode Duration 2 | 59/112 | 19/43 | 78/155 | 5/16 | 3/6 | 8/22 |
53% | 44% | 50% | 31% | 50% | 36% | |
Number of Emesis 2 | 52/110 | 6/16 | 70/154 | 6/16 | 2/4 | 8/20 |
47% | 41% | 45% | 38% | 50% | 40% | |
Nausea Severity 2 | 47/111 | 21/46 | 68/157 | 7/18 | 4/7 | 11/25 |
42% | 46% | 43% | 39% | 57% | 40% | |
Episode Improvement 3 | 88/123 | 39/54 | 127/177 | 12/18 | 5/7 | 17/25 |
72% | 72% | 72% | 67% | 71% | 68% | |
Side Effects Reported | 72/139 | 30/63 | 102/202 | 0/20 | 0/8 | 0/28 |
52% | 48% | 50% | 0% | 0% | 0% | |
Discontinued Therapy Due to Side Effects | 29/137 | 13/61 | 42/198 | 0/20 | 0/8 | 0/28 |
21% | 21% | 21% | 0% | 0% | 0% | |
Subject Statement of Risks V. Benefits 4 | 49/94 | 14/40 | 63/134 | 13/16 | 4/6 | 17/22 |
52% | 35% | 47% | 81% | 67% | 77% | |
Subjects' Recommendation 5 | 65/103 | 23/39 | 88/142 | 12/19 | 4/6 | 16/25 |
63% | 59% | 62% | 63% | 67% | 64% | |
Subject on Therapy at Time of Survey | 68/111 | 30/48 | 98/159 | 14/19 | 6/7 | 20/26 |
61% | 63% | 62% | 74% | 86% | 77% | |